Clinical Trial Update: Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase 3 trial evaluating a recombinant ESAT6-CFP10 allergen for diagnosing tuberculosis in children.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• ESAT6-CFP10 Allergen (recombinant) (ESAT6-CFP10)

Snippet

Sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Conditions: Tuberculosis Diagnosis | Phase 3 | Status: COMPLETED